TG Therapeutics, Inc. (TGTX) P/E Ratio History
Historical price-to-earnings valuation from 2011 to 2026
Loading P/E history...
TGTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, TG Therapeutics, Inc. (TGTX) trades at a price-to-earnings ratio of 15.2x, with a stock price of $41.97 and trailing twelve-month earnings per share of $2.89.
The current P/E is 91% below its 5-year average of 178.2x. Over the past five years, TGTX's P/E has ranged from a low of 0.0x to a high of 1708.0x, placing the current valuation at the 54th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TGTX trades at a 32% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, TGTX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TGTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TGTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $109B | 27.9 | 3.37Best | +837% | |
| $6B | 24.7 | - | -34% | |
| $28B | 21.6 | - | -21% | |
| $170B | 358.7 | - | -92% | |
| $363B | 86.5 | - | -1% | |
| $20B | 15.6Lowest | - | +4173%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TGTX Historical P/E Data (2011–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $33.22 | $2.86 | 11.6x | -93% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $29.81 | $2.77 | 10.8x | -94% |
| FY2025 Q3 | $36.13 | $2.78 | 13.0x | -93% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $35.99 | $0.37 | 97.0x | -46% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $39.43 | $0.24 | 161.4x | -9% |
| FY2024 Q4 | $30.10 | $0.14 | 215.0x | +21% | |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $17.79 | $0.60 | 29.6x | -83% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $15.21 | $0.22 | 70.2x | -61% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $17.08 | $0.01 | 1708.0x | +858% |
| FY2011 Q4 | Sat Dec 31 2011 00:00:00 GM | $1.13 | $80.96 | 0.0x | -100% |
| FY2011 Q3 | Fri Sep 30 2011 00:00:00 GM | $6.19 | $81.22 | 0.1x | -100% |
| FY2011 Q2 | $16.88 | $82.55 | 0.2x | -100% |
Average P/E for displayed period: 178.2x
See TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TGTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
Is TGTX stock overvalued or undervalued?
TGTX trades at 15.2x P/E, below its 5-year average of 178.2x. At the 54th percentile of historical range, the stock is priced at a discount to its own history.
How does TGTX's valuation compare to peers?
TG Therapeutics, Inc. P/E of 15.2x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is TGTX's PEG ratio?
TGTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2026.